Novo Nordisk seeks to reassure investors with new drug pipeline
At a capital markets day, Novo's CEO acknowledged investor doubts and outlined plans to compete with Eli Lilly and launch several multibillion-dollar products.
Novo Nordisk's chief executive opened the company's capital markets day by conceding that leadership must work to convince investors the company has a strong future. The admission follows reports of growing investor unease over the company's strategy.
The two Fierce articles covering the event are identical, both quoting CEO Mike Doustdar's opening remarks. A separate report from BioPharma Dive adds that the event took place in London and that executives presented a roadmap aimed at competing more effectively with Eli Lilly, including plans to bring forward several products expected to generate billions in annual sales.
The sources agree on the core message: Novo is under pressure to demonstrate growth beyond its current portfolio. The BioPharma Dive report places more emphasis on the competitive threat from Lilly, while the Fierce articles focus on the direct-to-consumer plans and blockbuster ambitions mentioned in the headline.
Sources · 3
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.